Innovotech Inc. (TSX-V: IOT) announced record revenues for the third quarter of 2025, reporting $1,267,692 in revenue and a net income of $92,945. On a year-to-date basis, the company has generated $3,410,204 in revenue. The record performance is attributed to growing demand for antimicrobial contract research services, strong results from its wholly-owned subsidiary Keystone Labs, and increased product sales.
“The Company has been building a foundation for continued growth and making multiple parallel efforts and investments to support expansion,” said Craig Milne, CEO. ”We are pleased to see the financial performance reflecting the changes underway.”
Innovotech is a diversified Canadian technology company with operations in specialized laboratory services, biotechnology, and proprietary intellectual property. Its subsidiary, Innovotech Labs Corporation, provides antimicrobial testing services and commercializes antimicrobial silver solutions. More information is available at www.innovotech.ca. Keystone Labs Inc., a DEL-accredited lab, serves the Canadian pharmaceutical and industrial markets, with details at www.keystonelabs.ca. Additionally, Innovotech holds a 60% stake in NouLifeSciences Inc., which owns intellectual property related to antioxidant molecules for cosmetics and medical applications.
The record revenue underscores the company's successful strategy in expanding its contract research and analytical services amid growing demand for antimicrobial solutions. This financial milestone is significant as it reflects the effectiveness of Innovotech's investments in growth initiatives and positions the company for continued success in the biotechnology sector.
